Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

Evandro De Azambuja, Andrew P. Holmes, Martine Piccart-Gebhart, Eileen Holmes, Serena Di Cosimo, Ramona F. Swaby, Michael Untch, Christian Jackisch, Istvan Lang, Ian Smith, Frances Boyle, Binghe Xu, Carlos H. Barrios, Edith A. Perez, Hatem A. Azim, Sung Bae Kim, Sherko Kuemmel, Chiun Sheng Huang, Peter Vuylsteke, Ruey Kuen HsiehVera Gorbunova, Alexandru Eniu, Lydia Dreosti, Natalia Tavartkiladze, Richard D. Gelber, Holger Eidtmann, José Baselga

Research output: Contribution to journalArticlepeer-review

292 Scopus citations

Fingerprint

Dive into the research topics of 'Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response'. Together they form a unique fingerprint.

Medicine & Life Sciences